Last update 11 Jun 2025

EGFR Degraders 9 (Dana-Farber Cancer Institute)

Overview

Basic Info

Drug Type
Proteolysis-targeting chimeras (PROTAC)
Synonyms-
Target
EGFR
Action
antagonists
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Therapeutic Areas
NeoplasmsRespiratory Diseases
Active Indication-
Inactive Indication
EGFR-mutated non-small Cell Lung Cancer
Originator Organization
Dana-Farber Cancer Institute, Inc.Dana-Farber Cancer Institute, Inc.Harvard Medical SchoolHarvard Medical School
Active Organization-
Inactive Organization
Dana-Farber Cancer Institute, Inc.Dana-Farber Cancer Institute, Inc.Harvard Medical SchoolHarvard Medical School
License Organization-
Drug Highest PhasePendingPreclinical
First Approval Date-
Regulation-

Structure/Sequence

Molecular FormulaC55H60N8O12S
InChIKeyNQLZSRAQWCFGSA-UHFFFAOYSA-N
CAS Registry-

Related

100 Clinical Results associated with EGFR Degraders 9 (Dana-Farber Cancer Institute)
Login to view more data
100 Translational Medicine associated with EGFR Degraders 9 (Dana-Farber Cancer Institute)
Login to view more data
100 Patents (Medical) associated with EGFR Degraders 9 (Dana-Farber Cancer Institute)
Login to view more data
100 Deals associated with EGFR Degraders 9 (Dana-Farber Cancer Institute)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR-mutated non-small Cell Lung CancerPreclinical
United States
Dana-Farber Cancer Institute, Inc.Dana-Farber Cancer Institute, Inc.
09 Jul 2020
EGFR-mutated non-small Cell Lung CancerPreclinical
United States
Harvard Medical SchoolHarvard Medical School
09 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free